OBJECTIVE: We have noted that quantitative multiplex-methylation specific PCR (QM-MSP) analysis of a key panel of genes may be useful as an ancillary tool for ductal carcinoma in situ (DCIS) detection in breast tissue. In this study, we investigated aberrant promoter hypermethylation of four genes as a means to detect epigenetic alterations specific to breast carcinoma in the serum of patients with DCIS and invasive ductal carcinoma (IDC). METHODS: Two hundred forty-three serum samples from 89 patients with IDC, 30 patients with DCIS, and 125 age-matched healthy controls were examined. After DNA extraction and sodium bisulfite treatment, QM-MSP was performed for HIN-1, RASSF1A, RAR-beta, and Twist. RESULTS: Overall significant differences in methylation levels were observed for HIN-1 (p=0.006), RAR-beta (p<0.001), RASSF1A (p=0.004), and Twist (p<0.001). All four genes showed significantly higher methylation frequencies in DCIS or IDC than in control subjects (p<0.001 for all comparisons). However, methylation frequencies were not significantly different between DCIS and IDC. In receiver-operating characteristic analysis, the two-gene combination (RAR-beta/RASSF1A) showed the best performance in distinguishing DCIS/IDC from control samples. The estimated specificity of this two-gene panel for detecting DCIS/IDC was 88.8%, and its sensitivity was 94.1%. CONCLUSIONS: The quantitative detection of aberrant DNA methylation in serum samples may be a promising high throughput approach for the diagnosis of breast cancer including DCIS. Copyright (c) 2010 Elsevier Inc. All rights reserved.
OBJECTIVE: We have noted that quantitative multiplex-methylation specific PCR (QM-MSP) analysis of a key panel of genes may be useful as an ancillary tool for ductal carcinoma in situ (DCIS) detection in breast tissue. In this study, we investigated aberrant promoter hypermethylation of four genes as a means to detect epigenetic alterations specific to breast carcinoma in the serum of patients with DCIS and invasive ductal carcinoma (IDC). METHODS: Two hundred forty-three serum samples from 89 patients with IDC, 30 patients with DCIS, and 125 age-matched healthy controls were examined. After DNA extraction and sodium bisulfite treatment, QM-MSP was performed for HIN-1, RASSF1A, RAR-beta, and Twist. RESULTS: Overall significant differences in methylation levels were observed for HIN-1 (p=0.006), RAR-beta (p<0.001), RASSF1A (p=0.004), and Twist (p<0.001). All four genes showed significantly higher methylation frequencies in DCIS or IDC than in control subjects (p<0.001 for all comparisons). However, methylation frequencies were not significantly different between DCIS and IDC. In receiver-operating characteristic analysis, the two-gene combination (RAR-beta/RASSF1A) showed the best performance in distinguishing DCIS/IDC from control samples. The estimated specificity of this two-gene panel for detecting DCIS/IDC was 88.8%, and its sensitivity was 94.1%. CONCLUSIONS: The quantitative detection of aberrant DNA methylation in serum samples may be a promising high throughput approach for the diagnosis of breast cancer including DCIS. Copyright (c) 2010 Elsevier Inc. All rights reserved.
Authors: Viera Kajabova; Bozena Smolkova; Iveta Zmetakova; Katarina Sebova; Tomas Krivulcik; Vladimir Bella; Karol Kajo; Katarina Machalekova; Ivana Fridrichova Journal: Transl Oncol Date: 2013-06-01 Impact factor: 4.243
Authors: Xue Cao; Qiuqiong Tang; Tim Holland-Letz; Melanie Gündert; Katarina Cuk; Sarah Schott; Jörg Heil; Michael Golatta; Christof Sohn; Andreas Schneeweiss; Barbara Burwinkel Journal: Int J Mol Sci Date: 2018-03-19 Impact factor: 6.208
Authors: Vera Kloten; Birte Becker; Kirsten Winner; Michael G Schrauder; Peter A Fasching; Tobias Anzeneder; Jürgen Veeck; Arndt Hartmann; Ruth Knüchel; Edgar Dahl Journal: Breast Cancer Res Date: 2013-01-15 Impact factor: 6.466